Bio-Path Holdings Pre-Tax Profit Margin 2010-2025 | BPTH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Bio-Path Holdings pre-tax profit margin from 2010 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

Bio-Path Holdings Pre-Tax Profit Margin 2010-2025 | BPTH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Bio-Path Holdings pre-tax profit margin from 2010 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$95B
Zoetis (ZTS)	$66.3B
Takeda Pharmaceutical (TAK)	$46.8B
Daiichi Sankyo, - (DSNKY)	$41.7B
Summit Therapeutics (SMMT)	$18.2B
Sandoz Group AG (SDZNY)	$17.7B
Merck (MKKGY)	$17.2B
Astellas Pharma (ALPMY)	$16.9B
Shionogi (SGIOY)	$14.1B
United Therapeutics (UTHR)	$12.8B
Neurocrine Biosciences (NBIX)	$10B
IPSEN (IPSEY)	$8.6B
Orion OYJ (ORINY)	$8B
Madrigal Pharmaceuticals (MDGL)	$6.7B
Stevanato Group S.p.A (STVN)	$6.6B
Corcept Therapeutics (CORT)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$5.8B
Ono Pharmaceutical (OPHLF)	$5.5B
Grifols, S.A (GRFS)	$4.9B
Ionis Pharmaceuticals (IONS)	$4.5B
Soleno Therapeutics (SLNO)	$3.2B
Crinetics Pharmaceuticals (CRNX)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.3B
Recursion Pharmaceuticals (RXRX)	$2.2B
Hypermarcas (HYPMY)	$2.1B
NewAmsterdam Pharma (NAMS)	$1.8B
Centessa Pharmaceuticals (CNTA)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.5B
Guardian Pharmacy Services (GRDN)	$1.5B